Brepocitinib Shows Potential Breakthrough for Cutaneous Sarcoidosis
- Feb 6
- 2 min read
Priovant, a biotechnology company formed through a partnership between Pfizer and Roivant Sciences, has announced a "watershed moment" in the treatment of cutaneous sarcoidosis (CS). Results from the Phase 2 Beacon trial show that brepocitinib, a dual TYK2/JAK1 inhibitor, significantly improved skin lesions in patients with this rare and often disfiguring inflammatory disease.
Currently, there are no FDA-approved therapies for cutaneous sarcoidosis, a condition affecting approximately 40,000 adults in the U.S.. Patients frequently rely on off-label treatments like corticosteroids, which can be toxic over time. The Beacon trial is the first industry-sponsored, placebo-controlled study to generate a positive readout for this indication.
The trial enrolled 31 patients, testing daily oral doses of 45 mg and 15 mg against a placebo. The 45-mg arm achieved a 100% response rate across multiple endpoints, with all patients seeing at least a 10-point improvement on the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI). Furthermore, 62% of patients on the higher dose reached functional remission, compared to none in the placebo group.
According to Priovant CEO Ben Zimmer, the drug was well-tolerated, with no serious adverse events reported. Analysts at Leerink Partners described the findings as "exceptional," noting they substantially exceeded market expectations.
Following these results, Roivant expects to initiate a Phase 3 study in 2026 after consulting with the FDA. This adds to a growing momentum for brepocitinib, which is already under regulatory review for dermatomyositis and undergoing Phase 3 testing for non-infectious uveitis.
Financially, Roivant remains in a strong position to fund these late-stage trials, reporting a cash balance of 4.5billion. Sales for brepocitinib are forecast to potentially reach 2.3 billion by 2032.
🔖 Sources
Keywords: Brepocitinib for Cutaneous Sarcoidosis
Brepocitinib for Cutaneous Sarcoidosis
Comments